VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target

gurufocus.com · 2026-09-23

Vanda Pharmaceuticals (VNDA) Analyst Rating Update On October 10, 2023, Oppenheimer initiated coverage on Vanda Pharmaceuticals (VNDA), assigning a rating of

TickrTrends take: Oppenheimer's initiation of coverage with an Outperform rating and a price target of $10 per share provides external validation that aligns with TickrTrends' current Undervalued assessment of VNDA. A valuation-focused reader should monitor whether this analyst coverage attracts institutional interest to the Healthcare sector name and track how the stock responds to this third-party endorsement. The convergence between analyst optimism and the Undervalued designation suggests potential upside exists if market sentiment shifts toward the coverage thesis.

Read the full story at gurufocus.com →